Global Key SolutionsGKS
Guidance Documents/Guidance-Document/Multiple Endpoints in Clinical Trials: Guidance for Industry

Multiple Endpoints in Clinical Trials: Guidance for Industry

Detailed guidance document from FDA and regulatory agencies.

Document Details

Guidance Document

October 21, 2022

April 17, 2024

Center for Drug Evaluation and Research

d08a7428-0534-4dad-83d9-37a60fc5fe62

Related Documents

E8(R1) General Considerations for Clinical Studies

Guidance DocumentApril 8, 2022Center for Drug Evaluation and Research
View Details →

Homeopathic Drug Products Guidance for FDA Staff and Industry

Guidance DocumentDecember 7, 2022Center for Drug Evaluation and Research
View Details →

Population Pharmacokinetics: Guidance for Industry

Guidance DocumentFebruary 3, 2022Center for Drug Evaluation and Research
View Details →

Quick Actions

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Transform Regulatory Data into Actionable Intelligence

Join leading pharmaceutical and medical device companies who trust GKS for their regulatory compliance needs.

Try KeyPedia Today

Explore our real use cases and discover our features in depth.

Subscribe to our newsletter

Get the latest updates and insights delivered to your inbox

footer
Global Key Solutions
Regulatory Data Transformed
Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
[email protected]
Quick Links
KeyPedia™ Lite
Legal & Ethics
©2026, Global Key Solutions All rights reserved.